Allure Of Apellis Enhanced By Stellar Launch Of Syfovre
First GA Treatment Off To Strong Start
Rival Iveric may be in the process of being bought by Astellas but that has done nothing to dampen interest in Apellis and its geographic atrophy treatment Syfovre which was only launched in March yet reached Q1 sales of over $18m.
You may also be interested in...
On the heels of Apellis's wildly successful launch for the geographic atrophy drug Syfovre, the company's co-founder and CEO spoke with In Vivo about what it takes to go from a start-up to a commercial-stage company and about the importance of honesty in leadership.
The Boston-based biotech is weighing up its options as the fall-out from its failed IPF candidate casts a shadow over Galecto’s future.
Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.